Abstract
Metabolomics represents a more recent addition to the range of omics tools, which are increasingly used in clinical applications. By measuring the composition of small molecules in tissues, blood or urine, it provides a sensitive molecular readout often associated with disease and its states, especially in cancer. Changes in metabolism related to cancer are increasingly well understood and are seen as a major hallmark of cancer. This review covers metabolomics used in human breast cancers, with a focus on its application in clinical diagnostics. There are clear indications that metabolomics could be a useful addition to currently established clinical diagnostic tools for breast cancer, including the possibility to detect cancer and to predict treatment responses and survival rates from blood and tissue samples.
| Original language | English |
|---|---|
| Journal | Pathobiology |
| Volume | 82 |
| Issue number | 3-4 |
| Pages (from-to) | 153-165 |
| Number of pages | 13 |
| ISSN | 1015-2008 |
| DOIs | |
| Publication status | Published - 23.09.2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Fingerprint
Dive into the research topics of 'Metabolomics Biomarkers for Breast Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver